Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.

de Groen RAL, Schrader AMR, Kersten MJ, Pals ST, Vermaat JSP.

Haematologica. 2019 Dec;104(12):2337-2348. doi: 10.3324/haematol.2019.227272. Epub 2019 Nov 7. Review.

2.

High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites.

Elfrink S, de Winde CM, van den Brand M, Berendsen M, Roemer MGM, Arnold F, Janssen L, van der Schaaf A, Jansen E, Groenen PJTA, Eijkelenboom A, Stevens W, Hess CJ, van Krieken JH, Vermaat JSP, Cleven AHG, de Groen RAL, Neviani V, de Jong D, van Deventer S, Scheijen B, van Spriel AB.

Blood. 2019 Sep 19;134(12):946-950. doi: 10.1182/blood.2019001185. Epub 2019 Jul 31.

PMID:
31366619
3.

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavourable prognosis.

Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, Kerver ED, Scheepstra CG, Beerenschot H, Deenik W, Wegman J, Broers R, de Boer JD, Nijland M, van Wezel T, Veelken H, Spaargaren M, Cleven AH, Kersten MJ, Pals ST.

Haematologica. 2019 May 23. pii: haematol.2018.214122. doi: 10.3324/haematol.2018.214122. [Epub ahead of print]

4.

Generalized Molluscum Contagiosum Successfully Treated with Interferon-Alpha in a Patient with Folliculotropic Mycosis Fungoides.

Melchers RC, Willemze R, Jansen PM, Vermaat JSP, Vermeer MH, Quint KD.

Case Rep Dermatol. 2019 Feb 26;11(1):52-56. doi: 10.1159/000497349. eCollection 2019 Jan-Apr.

5.

High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Schrader AMR, Jansen PM, Vermeer MH, Kleiverda JK, Vermaat JSP, Willemze R.

Am J Surg Pathol. 2018 Nov;42(11):1488-1494. doi: 10.1097/PAS.0000000000001132.

PMID:
30113335
6.

High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.

Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP.

Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7. No abstract available.

PMID:
29514783
7.

Uncommon presentation of Zika fever or co-infection? - Authors' reply.

Grobusch MP, Karimi O, Schinkel J, Codrington J, Vreden SG, Vermaat JS, Stijnis C, Goorhuis A.

Lancet. 2016 Apr 30;387(10030):1813-4. doi: 10.1016/S0140-6736(16)30178-7. Epub 2016 Apr 28. No abstract available.

PMID:
27203499
8.

Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection.

Karimi O, Goorhuis A, Schinkel J, Codrington J, Vreden SGS, Vermaat JS, Stijnis C, Grobusch MP.

Lancet. 2016 Mar 5;387(10022):939-940. doi: 10.1016/S0140-6736(16)00502-X. Epub 2016 Feb 20. No abstract available.

PMID:
26906627
9.

Precision medicine in diffuse large B-cell lymphoma: hitting the target.

Vermaat JS, Pals ST, Younes A, Dreyling M, Federico M, Aurer I, Radford J, Kersten MJ; EHA Lymphoma Group, a Scientific Working Group of the European Hematology Association.

Haematologica. 2015 Aug;100(8):989-93. doi: 10.3324/haematol.2015.128371. No abstract available.

10.

High-grade angiosarcoma of the right atrium successfully targeted with total resection and reconstruction followed by adjuvant chemotherapy.

Vermaat JS, Yilmaz A, de Bruin PC, van Es HW, Post MC.

Clin Res Cardiol. 2014 Jun;103(6):499-500. doi: 10.1007/s00392-014-0686-2. Epub 2014 Feb 28. No abstract available.

PMID:
24578197
11.

Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.

Mans DA, Vermaat JS, Weijts BG, van Rooijen E, van Reeuwijk J, Boldt K, Daenen LG, van der Groep P, Rowland BD, Jans JJ, Roepman R, Voest EE, van Diest PJ, Verhaar MC, de Bruin A, Giles RH.

J Pathol. 2013 Sep;231(1):117-29. doi: 10.1002/path.4219.

PMID:
23744542
12.

Reduced cilia frequencies in human renal cell carcinomas versus neighboring parenchymal tissue.

Basten SG, Willekers S, Vermaat JS, Slaats GG, Voest EE, van Diest PJ, Giles RH.

Cilia. 2013 Jan 31;2(1):2. doi: 10.1186/2046-2530-2-2.

13.

Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.

Vermaat JS, Gerritse FL, van der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH, Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB, Voest EE.

Eur Urol. 2012 Oct;62(4):685-95. doi: 10.1016/j.eururo.2012.01.020. Epub 2012 Jan 23.

PMID:
22285764
14.

Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment.

Vermaat JS, Nijman IJ, Koudijs MJ, Gerritse FL, Scherer SJ, Mokry M, Roessingh WM, Lansu N, de Bruijn E, van Hillegersberg R, van Diest PJ, Cuppen E, Voest EE.

Clin Cancer Res. 2012 Feb 1;18(3):688-99. doi: 10.1158/1078-0432.CCR-11-1965. Epub 2011 Dec 15.

15.

Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer.

Kloosterman WP, Hoogstraat M, Paling O, Tavakoli-Yaraki M, Renkens I, Vermaat JS, van Roosmalen MJ, van Lieshout S, Nijman IJ, Roessingh W, van 't Slot R, van de Belt J, Guryev V, Koudijs M, Voest E, Cuppen E.

Genome Biol. 2011 Oct 19;12(10):R103. doi: 10.1186/gb-2011-12-10-r103.

16.

Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids.

Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, Gerritsen MG, Schipper HS, Backer MJ, van Amersfoort M, Vermaat JS, Moerer P, Ishihara K, Kalkhoven E, Beijnen JH, Derksen PW, Medema RH, Martens AC, Brenkman AB, Voest EE.

Cancer Cell. 2011 Sep 13;20(3):370-83. doi: 10.1016/j.ccr.2011.08.010.

17.

Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance.

Schackmann RC, van Amersfoort M, Haarhuis JH, Vlug EJ, Halim VA, Roodhart JM, Vermaat JS, Voest EE, van der Groep P, van Diest PJ, Jonkers J, Derksen PW.

J Clin Invest. 2011 Aug;121(8):3176-88. doi: 10.1172/JCI41695. Epub 2011 Jul 11.

18.

Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients.

Kroeze SG, Vermaat JS, van Brussel A, van Melick HH, Voest EE, Jonges TG, van Diest PJ, Hinrichs J, Bosch JL, Jans JJ.

Eur J Cancer. 2010 Dec;46(18):3375-82. doi: 10.1016/j.ejca.2010.07.018. Epub 2010 Aug 13.

PMID:
20709525
19.

Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF.

Langenberg MH, Nijkamp MW, Roodhart JM, Snoeren N, Tang T, Shaked Y, van Hillegersberg R, Witteveen PO, Vermaat JS, Kranenburg O, Kerbel RS, Medema RH, Borel Rinkes IH, Voest EE.

Cancer Biol Ther. 2010 May 1;9(9):743-8. Epub 2010 May 18.

PMID:
20215863
20.

Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients.

Roodhart JM, Langenberg MH, Vermaat JS, Lolkema MP, Baars A, Giles RH, Witteveen EO, Voest EE.

Neoplasia. 2010 Jan;12(1):87-94.

21.

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.

Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, Groenewegen G, Giles RH, Schellens JH, Beijnen JH, Voest EE.

Ann Oncol. 2010 Jul;21(7):1472-81. doi: 10.1093/annonc/mdp559. Epub 2009 Dec 18.

PMID:
20022911
22.

Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.

Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijnen JH, Schellens JH, Voest EE.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4474-81.

23.

Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients.

Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE.

Ann Oncol. 2004 Jan;15(1):139-45.

PMID:
14679134
24.

Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518.

Crul M, Beerepoot LV, Stokvis E, Vermaat JS, Rosing H, Beijnen JH, Voest EE, Schellens JH.

Cancer Chemother Pharmacol. 2002 Dec;50(6):473-8. Epub 2002 Oct 25.

PMID:
12451474

Supplemental Content

Loading ...
Support Center